• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Endocrine Toxicities of Antineoplastic Therapy.抗肿瘤治疗的内分泌毒性
Cancers (Basel). 2021 Jan 14;13(2):294. doi: 10.3390/cancers13020294.
2
Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.脊柱立体定向放射外科联合酪氨酸激酶抑制剂治疗转移性肾细胞癌。
J Neurosurg Spine. 2016 Dec;25(6):766-774. doi: 10.3171/2016.4.SPINE16229. Epub 2016 Jul 8.
3
Emerging tyrosine kinase inhibitors for the treatment of renal cancer.用于治疗肾癌的新型酪氨酸激酶抑制剂
Expert Opin Emerg Drugs. 2015 Sep;20(3):379-92. doi: 10.1517/14728214.2015.1047761. Epub 2015 May 19.
4
More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds.十多年来酪氨酸激酶抑制剂在实体瘤治疗中的应用：我们所学到的以及未来的展望。
Biomark Insights. 2015 Oct 8;10(Suppl 3):33-40. doi: 10.4137/BMI.S22436. eCollection 2015.
5
Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.与癌症免疫疗法协同作用的酪氨酸激酶抑制剂的免疫后果。
Cancer Cell Microenviron. 2015;2(1). doi: 10.14800/ccm.677.
6
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.人非小细胞肺癌中表皮生长因子受体-酪氨酸激酶抑制剂获得性耐药的当前机制及更新的治疗策略
J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613.
7
Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology.受体酪氨酸激酶抑制剂在癌症药物治疗中的毒性：临床药理学管理
Curr Drug Metab. 2017;18(3):186-198. doi: 10.2174/1389200218666170105165832.
8
Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.研发中的用于头颈部肿瘤的多靶点激酶抑制剂。
Expert Opin Investig Drugs. 2019 Apr;28(4):351-363. doi: 10.1080/13543784.2019.1581172. Epub 2019 Feb 26.
9
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.癌症治疗中抗血管生成受体酪氨酸激酶抑制剂的最新进展。
J Hematol Oncol. 2019 Mar 12;12(1):27. doi: 10.1186/s13045-019-0718-5.
10
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.表皮生长因子受体酪氨酸激酶抑制剂相关治疗毒性风险：吉非替尼、厄洛替尼和阿法替尼治疗晚期表皮生长因子受体突变型非小细胞肺癌临床试验的荟萃分析。
J Thorac Oncol. 2017 Apr;12(4):633-643. doi: 10.1016/j.jtho.2016.11.2236. Epub 2016 Dec 19.

引用本文的文献

1
Endocrine Adverse Events Induced by Cancer Treatments: The Role of F-Fluorodeoxyglucose Positron Emission Tomography.癌症治疗引起的内分泌不良事件：F-氟脱氧葡萄糖正电子发射断层扫描的作用
Cancers (Basel). 2025 Aug 14;17(16):2651. doi: 10.3390/cancers17162651.
2
Anlotinib affects systemic lipid metabolism and induces lipid accumulation in human lung cancer cells.安罗替尼影响全身脂质代谢，并诱导人肺癌细胞内脂质堆积。
Lipids Health Dis. 2023 Aug 23;22(1):134. doi: 10.1186/s12944-023-01907-y.
3
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System.靶向血管内皮生长因子受体的抗癌酪氨酸激酶抑制剂所致肾上腺功能不全：美国食品药品监督管理局不良事件报告系统分析
Cancers (Basel). 2022 Sep 22;14(19):4610. doi: 10.3390/cancers14194610.

本文引用的文献

1
Case Report: Ipilimumab-Induced Panhypophysitis: An Infrequent Occurrence and Literature Review.病例报告：伊匹木单抗诱发的全垂体炎：罕见病例及文献综述
Front Oncol. 2020 Dec 1;10:582394. doi: 10.3389/fonc.2020.582394. eCollection 2020.
2
THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors.内分泌疾病治疗学：多激酶抑制剂治疗的内分泌代谢效应。
Eur J Endocrinol. 2021 Jan;184(1):R29-R40. doi: 10.1530/EJE-20-0683.
3
Electrolyte Disorders Induced by Antineoplastic Drugs.抗肿瘤药物引起的电解质紊乱
Front Oncol. 2020 May 19;10:779. doi: 10.3389/fonc.2020.00779. eCollection 2020.
4
Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation.检查点抑制剂的免疫相关不良反应：对免疫失调的深入了解。
Clin Immunol. 2020 Apr;213:108377. doi: 10.1016/j.clim.2020.108377. Epub 2020 Mar 2.
5
Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors.目前关于蛋白酪氨酸激酶抑制剂治疗患者甲状腺相关不良事件的证据。
Drug Metab Rev. 2019 Nov;51(4):562-569. doi: 10.1080/03602532.2019.1687512. Epub 2019 Nov 13.
6
Thyroid profile during the alternative Sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma.转移性肾细胞癌患者在舒尼替尼2/1交替给药方案期间的甲状腺功能指标
Endocrine. 2020 Mar;67(3):597-604. doi: 10.1007/s12020-019-02088-4. Epub 2019 Nov 2.
7
Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.酪氨酸激酶抑制剂和免疫检查点抑制剂引起的甲状腺疾病。
Crit Rev Oncol Hematol. 2019 Sep;141:23-35. doi: 10.1016/j.critrevonc.2019.05.015. Epub 2019 May 31.
8
Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).免疫检查点抑制剂的内分泌和代谢不良反应：概述（内分泌学家应该知道什么）。
J Endocrinol Invest. 2019 Jul;42(7):745-756. doi: 10.1007/s40618-018-0984-z. Epub 2018 Nov 23.
9
Sexual quality of life in men and women after cancer.癌症患者的男女性生活质量。
Climacteric. 2019 Dec;22(6):553-557. doi: 10.1080/13697137.2018.1526893. Epub 2018 Oct 31.
10
Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors.专家意见：新型抗癌疗法的代谢并发症——酪氨酸激酶抑制剂。
Ann Endocrinol (Paris). 2018 Oct;79(5):574-582. doi: 10.1016/j.ando.2018.07.011. Epub 2018 Aug 1.

抗肿瘤治疗的内分泌毒性

Endocrine Toxicities of Antineoplastic Therapy.

作者信息

Puliani Giulia, Appetecchia Marialuisa

机构信息

Oncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.

Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.

出版信息

Cancers (Basel). 2021 Jan 14;13(2):294. doi: 10.3390/cancers13020294.

DOI:10.3390/cancers13020294
PMID:33466843
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7830439/
Abstract

In recent years, the prognosis of many solid tumors has improved markedly thanks to new treatment strategies, including tyrosine kinase inhibitors (TKIs) and immunotherapy [...].

摘要

近年来，由于包括酪氨酸激酶抑制剂（TKIs）和免疫疗法在内的新治疗策略，许多实体瘤的预后有了显著改善。